The single-insider purchase by RA Capital (a 10% owner/Director) is a standalone bullish signal per insider-trading literature, though at 0.12% of market cap it is not large enough to force immediate re-rating. Monitor for additional insider buying or a material event filing (pipeline catalyst, partnership, financing) that could explain the concentrated buying.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $9.70entry
- T+1 · 5mo ago +1.03%α +1.17% · $9.80
- T+5 · 4mo ago −2.68%α −3.28% · $9.44
- T+20 · 4mo ago +6.39%α +7.42% · $10.32
- T+60 · 8w ago −22.78%α −25.52% · $7.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
RA Capital Management, a 10% owner and director at Artiva Biotherapeutics, purchased ~32.9K shares for $292K over two days.
Key Financial Metrics
Key Facts
- RA Capital Management, a 10% owner/Director, bought 31K shares at $8.88 ($275K) on 6/25 and 1.9K shares at $8.98 ($17K) on 6/26
- Total insider purchase value: $292K
- Purchase represents ~0.12% of $242M market cap
- ARTV has 92% analyst bullish rating (4 Strong Buy, 7 Buy, 1 Hold)
Financial Impact
$292K insider purchase, ~0.12% of market cap
Risk Factors
- Purchase value is small relative to market cap (0.12%), limiting signal strength
- Insider buying preceded by strong recent price performance (+35% on prior report) creates potential mean-reversion risk
- Biotech sector binary risk (pipeline failure, financing overhang) independent of insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001231919-26-000711 |
Track record
33 reports on ARTV
10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers